We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+20.49%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$1.73B
AUM Growth
+$225M
Cap. Flow
-$21.6M
Cap. Flow %
-1.25%
Top 10 Hldgs %
47.96%
Holding
98
New
32
Increased
17
Reduced
16
Closed
27

Top Buys

Rank Stock Value
1
SUPN icon
Supernus Pharmaceuticals
SUPN
+$41.6M
2
WSM icon
Williams-Sonoma
WSM
+$31.1M
3
DECK icon
Deckers Outdoor
DECK
+$29.3M
4
BMY icon
Bristol-Myers Squibb
BMY
+$28.6M
5
AZO icon
AutoZone
AZO
+$28.5M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$50.8M
2
ENR icon
Energizer
ENR
+$34.9M
3
FL
Foot Locker
FL
+$26.5M
4
DPLO
DIPLOMAT PHARMACY, INC.
DPLO
+$26.5M
5
TGT icon
Target
TGT
+$25.7M

Sector Composition

Rank Sector Weight
1 Healthcare 41.99%
2 Consumer Discretionary 17.1%
3 Consumer Staples 5.85%
4 Technology 2.89%
5 Industrials 0.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IWM icon
1
PUT
iShares Russell 2000 ETF
IWM
$80.9B
$232M 13.38%
14,000
+8,000
+133% +$1.26M
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$193M 11.14%
6,000
-2,000
-25% -$616K
AVTX icon
3
Avalo Therapeutics
AVTX
$976M
$111M 6.43%
7,182
– –
AMAG
4
DELISTED
AMAG Pharmaceuticals
AMAG
$49.4M 2.85%
4,060,000
– –
EPC icon
5
CALL
Edgewell Personal Care
EPC
$1.27B
$46.4M 2.68%
15,000
– –
VNDA icon
6
Vanda Pharmaceuticals
VNDA
$312M
$46.4M 2.68%
2,828,000
-720,000
-20% -$10.9M
SUPN icon
7
Supernus Pharmaceuticals
SUPN
$2.68B
$40.6M 2.34%
+1,712,000
New +$41.6M
BIIB icon
8
Biogen
BIIB
$29.9B
$38M 2.19%
128,000
-20,000
-14% -$5.55M
REGN icon
9
Regeneron Pharmaceuticals
REGN
$68.8B
$37.5M 2.17%
100,000
-48,000
-32% -$16.1M
PTCT icon
10
PTC Therapeutics
PTCT
$6.37B
$36.4M 2.1%
758,000
+622,000
+457% +$26.4M
BHVN
11
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$33.3M 1.92%
612,000
+34,000
+6% +$1.68M
WSM icon
12
Williams-Sonoma
WSM
$26.7B
$32.8M 1.89%
+894,412
New +$31.1M
BMY icon
13
Bristol-Myers Squibb
BMY
$127B
$32.1M 1.85%
+500,000
New +$28.6M
DECK icon
14
Deckers Outdoor
DECK
$13.3B
$31.1M 1.79%
+1,104,600
New +$29.3M
BLUE
15
DELISTED
bluebird bio
BLUE
$29.5M 1.7%
+25,939
New +$28.2M
AZO icon
16
AutoZone
AZO
$48.3B
$29.4M 1.69%
+24,651
New +$28.5M
CMG icon
17
Chipotle Mexican Grill
CMG
$40.8B
$28.2M 1.63%
1,687,100
+187,100
+12% +$3M
DBX icon
18
Dropbox
DBX
$6.81B
$26.1M 1.51%
1,458,000
+458,000
+46% +$8.63M
CENTA icon
19
Central Garden & Pet Co Class A
CENTA
$2.41B
$25.8M 1.49%
+1,097,500
New +$24.7M
NVST icon
20
Envista
NVST
$4.28B
$25.1M 1.45%
+848,000
New +$24.1M
ENTA icon
21
Enanta Pharmaceuticals
ENTA
$372M
$24.3M 1.4%
393,895
-186,105
-32% -$11.5M
INCY icon
22
Incyte
INCY
$23.5B
$24M 1.39%
275,000
-153,000
-36% -$13.1M
FTDR icon
23
Frontdoor
FTDR
$5.02B
$23.7M 1.37%
500,000
+108,000
+28% +$5.06M
ASMB icon
24
Assembly Biosciences
ASMB
$506M
$23.7M 1.36%
96,333
-109,334
-53% -$20.1M
AVYA
25
DELISTED
Avaya Holdings Corp. Common Stock
AVYA
$22.8M 1.32%
1,692,000
+1,172,000
+225% +$14.4M
1
2 3 4

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
DWM
Diversify Wealth Management Sandy, Utah $5.61B AUM 19.63% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
AIM
Alphinity Investment Management Sydney, Australia $5.68B AUM 26.72% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return

Armistice Capital's Q4 2019 Portfolio in Review

As of Q4 2019, Armistice Capital held 98 positions worth $1.73B, up 15% from $1.51B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Armistice Capital's Q4 2019 filing shows 32 new, 17 increased, 16 reduced and 27 closed positions. Its largest new stake was Supernus Pharmaceuticals: 1,712,000 shares worth $40.6M. The largest sale was Celgene Corp, an estimated $50.8M.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 35% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

  • Armistice Capital's largest Q4 2019 buy was Supernus Pharmaceuticals: 1,712,000 shares worth $40.6M.
  • Armistice Capital added most to PTC Therapeutics in Q4 2019, an estimated $26.4M increase.
  • Armistice Capital's biggest Q4 2019 reduction was Kraft Heinz, cutting an estimated $24.5M.
  • Armistice Capital fully exited Celgene Corp in Q4 2019, selling an estimated $50.8M.
  • Armistice Capital's ten largest holdings make up 48% of its $1.73B portfolio in Q4 2019.
  • Armistice Capital opened 32 new positions and closed 27 in Q4 2019.
  • Armistice Capital's portfolio value rose 15% quarter-over-quarter to $1.73B.

Based on Armistice Capital's 13F filing for Q4 2019, filed 14 Feb 2020.